MAVERIC is a multi-center, randomized, double-blind, placebo-controlled Phase 3 trial assessing the impact of CardiolRx™ oral solution on the risk of pericarditis recurrence in adults currently being treated with rilonacept (Arcalyst®).

The study is enrolling at 20+ research sites across 13 U.S. states.

Recurrent pericarditis is repeated inflammation of the pericardium, the protective sac surrounding the heart. Characterized by sharp chest pain, shortness of breath, and fatigue, it can result in repeated hospitalizations, emergency department visits, and significantly reduced quality of life.

MAVERIC is evaluating whether CardiolRx™ can reduce the risk of pericarditis recurrence when rilonacept is discontinued.

CardiolRx™ is a pharmaceutically manufactured oral solution. Research suggests the active ingredient attenuates multiple inflammatory signaling pathways, including inhibiting activation of the NLRP3 inflammasome, a key driver of pericarditis recurrence.

For additional information: cardiolrx.com

CardiolRx™ is an investigational product not approved by the U.S. FDA.

• ✓18 years of age or older
• ✓Diagnosis of recurrent pericarditis
• ✓Currently treated with rilonacept (Arcalyst®) for ≥12 months
• ✓Free of pericarditis recurrence for ≥6 months
• ✓Rilonacept dose unchanged for ≥3 months before enrolment
• ✓Pericarditis pain score ≤2 on a 0–10 scale for ≥7 days before randomization
• ✓C-Reactive Protein (CRP) <1.0 mg/dL at screening

Additional criteria apply. Eligibility is confirmed by study site staff during screening.